Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Sanchez-Luna, M.; Burgos-Pol, R.; Oyagüez, I.; Figueras-Aloy, J.; Sánchez-Solís, M.; Martinón-Torres, F.; Carbonell-Estrany, X.

doi:10.6084/m9.figshare.c.3907168_D1.v1

12879_2017_2803_MOESM1_ESM.docx (19.41 kB)

Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

journal contribution

posted on 2017-10-17, 05:00 authored by M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres, X. Carbonell-Estrany

Curve fitting to get the palivizumab effect on recurrent wheezing over 61 years by using RR values from the literature. (DOCX 19 kb)

Funding

Fundación Instituto para la Mejora de la Asistencia Sanitaria

History

Usage metrics

Keywords

Cost-effectiveness Preterm infants Palivizumab RSV infection Recurrent wheezing

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Funding

Fundación Instituto para la Mejora de la Asistencia Sanitaria

History

Usage metrics

Categories

Keywords

Licence

Exports